3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Tumor-Agnostic
9
Thoracic
8
Head & Neck
3
Gastrointestinal
3
Sarcoma
2
Gynecologic
2
Genitourinary
2
Other hematologic neoplasm
1
Dermatologic
1
Breast
1
Conditions
Sarcoma
8
Melanoma
3
Hemangiosarcoma
3
Breast Neoplasms
3
Prostatic Neoplasms
2
Osteosarcoma
2
Neoplasms
2
Leiomyosarcoma
2
Carcinosarcoma
2
Carcinoma, Endometrioid
2
Vascular Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Tertiary Lymphoid Structures
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma, Synovial
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Liposarcoma
1
Kidney Neoplasms
1
Histiocytoma, Malignant Fibrous
1
Hemangioendothelioma, Epithelioid
1
Interventions
Cyclophosphamide
17
pembrolizumab
12
Doxorubicin
10
fludarabine
7
Irinotecan
7
Blood Specimen Collection
7
Temozolomide
6
Gemcitabine
6
Etoposide
6
Radiotherapy
5
Ifosfamide
5
Carboplatin
5
Albumin-Bound Paclitaxel
5
tecogalan
4
cemiplimab
4
Vincristine
4
Trabectedin
4
Paclitaxel
4
Nivolumab
4
Filgrastim
4
Drug Therapy
4
Dexamethasone
4
Bevacizumab
4
pazopanib
3
olaparib
3
nilotinib
3
dostarlimab
3
aflibercept
3
Therapeutics
3
Taxes
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplasms
×
durvalumab
×
Sarcoma
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled
NCT02423863
2020-12-17
Poly-ICLC
Oncovir, Inc.
Phase 2
Completed
26 enrolled